Document Detail


Effects of telmisartan therapy on metabolic profiles and serum high molecular weight (HMW)-adiponectin level in Japanese male hypertensive subjects with abdominal obesity.
MedLine Citation:
PMID:  19403983     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: Telmisartan, an angiotensin II receptor blocker (ARB), was reported to have partial peroxisome proliferator-activated receptor gamma (PPAR gamma) activity in vitro. Also, adipocyte-derived protein adiponectin, especially its high molecular weight (HMW) form, has been reported to have beneficial effects on insulin resistance and atherosclerosis. We investigated the effects of 3-month telmisartan therapy on various metabolic parameters, including serum HMW adiponectin and high-sensitivity C-reactive protein (hs-CRP) levels in male hypertensive subjects with abdominal obesity.
METHODS: This study included 19 Japanese male hypertensive subjects, aged 51.2+/-7.6 (mean+/-SD) years, and body mass index 27.7+/-4.1 kg/m(2). In these subjects, 14 were naive to telmisartan treatment (40.0+/-15.7 mg daily), and 5 were changed from other ARBs to telmisartan. Serum HMW adiponectin concentration was assayed using HMW-selective ELISA kit.
RESULTS: In all 19 subjects, systolic/diastolic blood pressure (BP) decreased from 153/98 to 134/85 mmHg (p<0.001 for both). Serum HMW-adiponectin level increased from 2.06+/-0.81 to 2.40+/-0.96 microg/mL (+16.4%, p=0.017). Body weight, glucose, insulin, lipids and hs-CRP did not change during the study period, and there were no adverse effects in any subject. In the newly administered group (n=14), the results were almost the same: BP decreased from 155/98 to 134/84 mmHg (p=0.0015 for both), and serum HMW-adiponectin level increased from 2.07+/-0.68 to 2.39+/-0.99 microg/mL (+15.5%, p=0.089).
CONCLUSION: These data suggest that telmisartan therapy is efficient for controlling BP, and may exert beneficial effects on HMW adiponectin in male hypertensive subjects with abdominal obesity.
Authors:
Naoko Komiya; Hiroshi Hirose; Hiroshi Kawabe; Hiroshi Itoh; Ikuo Saito
Related Documents :
19099313 - Plasma sflt-1-to-plgf ratio is correlated with inflammatory but not with oxidative stre...
16237393 - Changes of sleep architecture, spectral composition of sleep eeg, the nocturnal secreti...
21968853 - Vitamin d supplementation versus combined calcium and vitamin d in older female patient...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-04-30
Journal Detail:
Title:  Journal of atherosclerosis and thrombosis     Volume:  16     ISSN:  1880-3873     ISO Abbreviation:  J. Atheroscler. Thromb.     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2009-05-28     Completed Date:  2009-10-29     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  9506298     Medline TA:  J Atheroscler Thromb     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  137-42     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adiponectin / blood*
Aged
Aged, 80 and over
Angiotensin II Type 1 Receptor Blockers / therapeutic use
Benzimidazoles / therapeutic use*
Benzoates / therapeutic use*
Female
Humans
Hypertension / drug therapy,  metabolism
Lipoproteins, LDL / blood,  drug effects
Male
Metabolome / drug effects*
Obesity / drug therapy,  metabolism
Sex Factors
Chemical
Reg. No./Substance:
0/Adiponectin; 0/Angiotensin II Type 1 Receptor Blockers; 0/Benzimidazoles; 0/Benzoates; 0/Lipoproteins, LDL; U5SYW473RQ/telmisartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Suitability of adsorption isotherms for predicting the retention capacity of active slag filters rem...
Next Document:  SPARC is a Major Secretory Gene Expressed and Involved in the Development of Proliferative Diabetic ...